



## Eledon Pharmaceuticals to Present at Two Investor Conferences in September

September 1, 2021

IRVINE, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced that management will present a corporate overview and participate in one-on-one investor meetings at the HC Wainwright 23<sup>rd</sup> Annual Global Investment Conference. The company's presentation will be available on-demand beginning on **Monday, September 13 at 7:00am EST.**

Management will also present a corporate overview and host one-on-one meetings during the Cantor Global Healthcare Conference. The presentation is scheduled for **Thursday, September 30 at 3:20pm EST.**

### **HC Wainwright 23<sup>rd</sup> Annual Global Healthcare Conference – September 13-15**

**Title:** Eledon Pharmaceuticals (ELDN) Company Presentation  
**Date:** Monday, September 13, 2021  
**Time:** 7:00 AM EST  
**Presenter:** David-Alexandre Gros, CEO  
**Registration Link:** [Here](#)

### **Cantor Global Healthcare Conference – September 27-30**

**Title:** Eledon Pharmaceuticals (ELDN) Company Presentation  
**Date:** Thursday, September 30, 2021  
**Time:** 3:20 PM EST  
**Presenter:** David-Alexandre Gros, CEO  
**Registration Link:** [Here](#)

#### **Replay:**

A replay of both presentations will be accessible for 90 days following the live sessions on the Events page of the Investors section on the Company's website at <https://ir.eledon.com/events-and-presentations/events>.

**If you are interested in arranging a one-on-one meeting request, please contact your bank conference representative.**

#### **About Eledon Pharmaceuticals and AT-1501**

Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501, an anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. AT-1501 is a humanized IgG1 antibody engineered to potentially both improve safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. The CD40L/CD40 pathway is widely recognized for its prominent role in immune regulation. CD40L is primarily expressed on activated CD4+ T cells, platelets and endothelial cells while the CD40 receptor is constitutively expressed on antigen presenting cells such as B cells, macrophages, and dendritic cells. By blocking CD40L and not the CD40 receptor, AT-1501 inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy compared to anti-CD40 receptor approaches. Blocking CD40L also increases polarization of CD4+ lymphocytes to Tregs, a specialized subpopulation of T cells that act to suppress an immune response, thus creating a more tolerogenic environment, which may also play a therapeutic role for autoimmune diseases and in the transplant setting. Eledon is headquartered in Irvine, Calif. For more information, please visit the company's website at [www.eledon.com](http://www.eledon.com).

Follow Eledon Pharmaceuticals on social media: [LinkedIn](#); [Twitter](#)

#### **Investor Contact**

Corey Davis, Ph.D.  
LifeSci Advisors  
212-915-2577  
[cdavis@lifesciadvisors.com](mailto:cdavis@lifesciadvisors.com)



Source: Eledon Pharmaceuticals, Inc.